Приказ основних података о документу
Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study
dc.creator | Rosania, Rosa | |
dc.creator | Von Arnim, Ulrike | |
dc.creator | Link, Alexander | |
dc.creator | Rajilić-Stojanović, Mirjana | |
dc.creator | Franck, Caspar | |
dc.creator | Canbay, Ali | |
dc.creator | Malfertheiner, Peter | |
dc.creator | Venerito, Marino | |
dc.date.accessioned | 2021-03-10T13:51:38Z | |
dc.date.available | 2021-03-10T13:51:38Z | |
dc.date.issued | 2018 | |
dc.identifier.issn | 1841-8724 | |
dc.identifier.uri | http://TechnoRep.tmf.bg.ac.rs/handle/123456789/4013 | |
dc.description.abstract | Background & Aims: A negative association between H. pylori and inflammatory bowel disease (IBD) has been previously reported. There were also case reports suggesting a new onset of IBD 6-12 months after H. pylori eradication therapy. In a case-control study we investigated whether previous H. pylori eradication therapy was associated with the risk of developing IBD. Methods: IBD outpatients with both Crohn's disease (CD) and ulcerative colitis (UC) were enrolled. Age- and sex-matched blood donors served as controls in a 1:2 fashion. Information on demographics, medical history, previous H. pylori infection and eradication therapy was recorded. Serum samples for H. pylori serology testing (anti-H. pylori-IgG and anti-CagA-IgG) were obtained. Controls that received H. pylori eradication therapy during the 12 months previous to enrollment were excluded. Results: Overall, 127 IBD patients (CD N= 90; UC N= 37) and 254 controls were enrolled. The prevalence of H. pylori infection (positive H. pylori serology and/or previous eradication) in IBD patients and controls was 11% and 23%, respectively (OR 0.4, 95% CI 0.21-0.74, p lt 0.003). Four patients (3%) developed IBD (3 MC and 1 CU) after receiving successful H. pylori eradication (latency 6-12 months). The rate of previous H. pylori eradication therapy in patents who successively developed IBD was lower but not statistically different from that observed in the control group (OR 0.43, 95% CI 0.14-1.29, p=0.16). Conclusions: In our study previous H. pylori eradication therapy was not associated with the onset of IBD. Whether in a subgroup of patients, H. pylori eradication therapy may trigger a latent IBD, cannot be excluded. | en |
dc.publisher | Medical Univ Press, Cluj-Napoca | |
dc.rights | restrictedAccess | |
dc.source | Journal of Gastrointestinal and Liver Diseases | |
dc.subject | Crohn's disease | en |
dc.subject | ulcerative colitis | en |
dc.subject | Helicobacter pylori | en |
dc.subject | inflammatory bowel disease | en |
dc.title | Helicobacter Pylori Eradication Therapy is Not Associated with the Onset of Inflammatory Bowel Diseases. A Case-Control Study | en |
dc.type | article | |
dc.rights.license | ARR | |
dc.citation.epage | 125 | |
dc.citation.issue | 2 | |
dc.citation.other | 27(2): 119-125 | |
dc.citation.rank | M23 | |
dc.citation.spage | 119 | |
dc.citation.volume | 27 | |
dc.identifier.doi | 10.15403/jgld.2014.1121.272.hpy | |
dc.identifier.pmid | 29922755 | |
dc.identifier.scopus | 2-s2.0-85049235903 | |
dc.identifier.wos | 000434805800002 | |
dc.type.version | publishedVersion |